Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial-Reference-Cited by-同舟云学术

Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial

Published:2020-01-31 Issue:11 Volume:26 Page:2603-2614
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Asleh Karama^ORCID,Brauer Heather Ann,Sullivan Amy,Lauttia Susanna,Lindman Henrik,Nielsen Torsten O.,Joensuu Heikki^ORCID,Thompson E. Aubrey,Chumsri Saranya

Funder

Breast Cancer Research Foundation

Bankhead-Coley Research Program

DONNA Foundation

Mayo Clinic

Canadian Cancer Society

Academy of Finland

Cancer Society of Finland

Sigrid Juselius Foundation

Helsinki University Central Hospital, Finland

Canadian Institutes of Health Research

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantifying mRNA in Highly Degraded Fixed Tissues by Nanostring Technology: A Comparative Study;Methods and Protocols;2024-05-07

2. Investigating the Immunogenic Cell Death-Dependent Subtypes and Prognostic Signature of Triple-Negative Breast Cancer;Phenomics;2024-02

3. Desvendando a neoplasia mamária triplo-negativa;Tudo é Ciência: Congresso Brasileiro de Ciências e Saberes Multidisciplinares;2023-12-20

4. Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial;Scientific Reports;2023-12-04

5. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial;Breast Cancer Research;2023-09-29